Nudge Spotlight Account Briefs
ED471901-4303-4CC6-BB60-61574FD72DB7 Created with sketchtool.
Eisai Pharmaceuticals Account Brief
Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, cure, and care of the health and well-being of people worldwide. The ability to conduct basic and clinical research in the United States strengthens Eisai's resources in the pharmaceutical market and helps the company meet highly competitive research and development goals, enhancing Eisai's proven ability to discover new medicines. Research facilities in the United States include Eisai Research Institute in Andover, Massachusetts; Eisai Medical Research Inc. in Ridgefield Park, New Jersey; and Eisai Inc.'s Research Triangle Park facility in North Carolina.
Eisai Pharmaceuticals Recent News Mentions Sep. 29, 2019
Eisai And Nichi-Iko Enter Into Collaboration Agreement For Generic Pharmaceutical Business In China
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China. The Chinese pharmaceutical market is the second largest market in the world after the United States, and the generic drugs account for more than 70% of its market in terms of value. Also, due to the rapid aging and the government's policies to promote the generic drug market, the continuous growth of generic drugs is predicted. Furthermore, in order to improve the quality of generic drugs, the Chinese government is establishing the stable supply system of high quality generic drugs equivalent to the original drugs, such as it introduces the generic quality consistency evaluation system and provides priority response to the government's centralized procurement system for the generic drugs which have passed its evaluation test. Under this agreement, Eisai and Nichi-Iko aim to enhance their pharmaceutical businesses in China by introducing the high quality generic drugs which Nichi-Iko maintains the marketing approval in Japan. Eisai and Nichi-Iko specifically select the appropriate products for the Chinese market needs, and Eisai's subsidiary in China sells the products after Nichi-Iko obtains the approval for import and sales in China. Eisai and Nichi-Iko will select the first two products in this fiscal year, and subsequently prepare to launch one to two products every year for the continuous launch from FY2024. Due to this agreement, Eisai will address a broader range of medical needs in China by further strengthening its Chinese generic business since entering in 2015. Nichi-Iko aims to enter the Chinese market leveraging the Eisai's business foundation in China, as part of the strategic imperatives, "Business Expansion" and "Global Operation" in the 8th Medium-term Management Plan "NEXUS∞". In March 2018, Eisai and Nichi-Iko has entered into a strategic alliance agreement for the generic pharmaceutical busi
See 3 more news mentions
Executives and decision-makers at Eisai Pharmaceuticals’s relationship intelligence platform can help you find the right executive to reach out to at Eisai Pharmaceuticals, such as Pat Forsythe, General Manager, or Paul Hawthorne, Senior Vice President, Americas Commercial. Then get in touch and start a conversation.
Pat Forsythe General Manager
Get in touch
Paul Hawthorne Senior Vice President, Americas Commercial
Get in touch
Eric Foster Vice President, Program And Alliance Management
Get in touch
Douglas Snyder Vice President And General Counsel
Get in touch
Evelyn D Shen Associate General Counsel, Intellectual Property
Get in touch
Neriman Botas Exec Vp Hr & Corp Communications
Get in touch
Jack Markey Senior Director
Get in touch
Neil West Vice President EMEA, Global Neurology Business Unit
Get in touch
Alex Scott Senior Vice President, Corporate Development
Get in touch
Shaji Procida President & COO
Get in touch
See 5 more decision makers
Connectors at Eisai Pharmaceuticals
Executives can be difficult to reach, but every company has connectors who bring together people and ideas. At Eisai Pharmaceuticals, people like Cynthia Schwalm, and David Trexler are likely connectors.
Cynthia Schwalm
Ask for intro
David Trexler
Ask for intro
Teresa Cronin Director, Corporate Advocacy
Ask for intro
See who in your network has relationships at Eisai Pharmaceuticals With you can uncover which contacts at a company your network is most strongly connected to. If you find a strong relationship, ask for an introduction!
Topics frequently mentioned alongside Eisai Pharmaceuticals
When Eisai Pharmaceuticals is mentioned in the news, often sees topics like Europe, and Leadership. If your conversation focuses on these topics, you’ll probably get Eisai Pharmaceuticals’s attention.
Companies frequently mentioned alongside Eisai Pharmaceuticals
When Eisai Pharmaceuticals is mentioned in the news, companies such as PR Newswire, Abbvie, and Nomura Securities International are often also mentioned. These companies can serve as customer examples.
Executives Get in touch with decision-makers at Eisai Pharmaceuticals. Sign up for Nudge Premium to:
See who in your network can offer a warm intro
Get insights on the company's key decision-makers
Start 30-day free trial now
Connectors Ask connectors at Eisai Pharmaceuticals for intros to execs. Sign up for Nudge Premium to:
See who in your network can offer a warm intro to connectors
Leverage your network to find pathways into new companies
Start 30-day free trial now
Recent News Don't waste time researching your targets. Sign up for Nudge Premium to:
Get notified when your target accounts are mentioned in the news
Get insights on target companies right within your inbox as you write emails
Start 30-day free trial now